Order Article Reprints

Bauckneht M, Rebuzzi SE, Ponzano M, Borea R, Signori A, Frantellizzi V, Lodi Rizzini E, Mascia M, Lavelli V, Miceli A, et al. Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. Cancers. 2022; 14(7):1744. https://doi.org/10.3390/cancers14071744

Bauckneht, Matteo, Sara Elena Rebuzzi, Marta Ponzano, Roberto Borea, Alessio Signori, Viviana Frantellizzi, Elisa Lodi Rizzini, Manlio Mascia, Valentina Lavelli, Alberto Miceli, and et al. 2022. "Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study" Cancers 14, no. 7: 1744. https://doi.org/10.3390/cancers14071744

Bauckneht, M., Rebuzzi, S. E., Ponzano, M., Borea, R., Signori, A., Frantellizzi, V., Lodi Rizzini, E., Mascia, M., Lavelli, V., Miceli, A., De Feo, M. S., Pisani, A. R., Nuvoli, S., Tripoli, V., Morganti, A. G., Mammucci, P., Caponnetto, S., Mantica, G., Di Nicola, A. D., ... Fornarini, G. (2022). Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. Cancers, 14(7), 1744. https://doi.org/10.3390/cancers14071744